This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The desmoid tumors market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.18 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to advancements in medical imaging, genetic research and understanding, surgical innovations, awareness and education, patient advocacy.
The desmoid tumors market size is expected to see strong growth in the next few years. It will grow to $4.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to targeted therapies, personalized medicine, expanded international collaborations, regulatory approvals for novel therapies, patient-centric approaches. Major trends in the forecast period include advancements in treatment approaches, precision medicine and biomarker discovery, clinical trials and research initiatives, multidisciplinary treatment teams, patient advocacy and support.
The increasing incidence of cancer is anticipated to drive the growth of the desmoid tumor market in the future. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade nearby tissues and organs, causing significant harm. The global rise in cancer cases has spurred demand for advanced and effective chemotherapeutic agents, positively impacting the desmoid tumor market. For example, in May 2024, according to the National Cancer Institute, a U.S.-based federal government agency, an estimated 2,001,140 new cases of cancer are expected to be diagnosed in the U.S. in 2024, with 611,720 projected deaths from the disease. In 2022, nearly 20 million new cases and 9.7 million cancer-related deaths were reported worldwide. By 2040, the annual number of new cancer cases is expected to increase to 29.9 million, with cancer-related deaths projected to reach 15.3 million. Consequently, the rising cancer cases are driving the growth of the desmoid tumor market.
The increasing allocation of government funding for research and development is expected to boost the desmoid tumor market. Government funding plays a pivotal role in advancing tumor research and treatment by providing financial support for scientific studies, medical infrastructure, and improved access to care. This ultimately enhances cancer prevention, diagnosis, and patient outcomes. An example is the budget of $7.3 billion allocated to the National Cancer Institute by the United States Congress in fiscal year 2023 for the Cancer Moonshot, marking a $408 million increase from 2022. Consequently, the escalating government funding for research and development is fostering the growth of the desmoid tumor market.
Key companies in the desmoid tumors market are focusing on developing innovative drugs, such as nirogacestat, to address the needs of their existing consumers more effectively. Nirogacestat, an oral, small-molecule gamma-secretase inhibitor, has shown promise for treating desmoid tumors by blocking the production of notch proteins, contributing to tumor cell death. In February 2023, SpringWorks Therapeutics Inc. announced the acceptance and priority review of their new drug application (NDA) for nirogacestat by the U.S. Food and Drug Administration (FDA). This development provides patients with a new treatment option that holds the potential to improve outcomes.
In January 2023, the merger of Advaxis Inc. with Ayala Pharmaceuticals Inc., a US-based biotechnology company, aims to create a unified entity focused on developing and commercializing Ayala's lead program, AL102, for desmoid tumor treatment. The merger intends to expedite the development and commercialization of AL102, fostering a more diversified and robust cancer portfolio. Ayala Pharmaceuticals Inc. is actively developing AL102, a vaccine candidate designed to address the treatment of desmoid tumors.
Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company, Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG.
North America was the largest region in the desmoid tumors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the desmoid tumors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The desmoid tumors market consists of revenues earned by entities by providing services such as gleevec-based therapy, sorafenib-based therapy, long-term monitoring, resonance imaging (MRI), computed tomography (CT) scans, ultrasound, and fine needle aspiration techniques (FNA) that aid in the diagnosis of desmoid tumors. The market value includes the value of related goods sold by the service provider or included within the service offering. The desmoid tumors market also includes sales of surgical tools, linear accelerators, immunotherapy drugs, and anti-fibrotic agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Desmoid tumors are rare non-cancerous (benign) growths originating from connective tissue cells, typically within the fascia - the tissue encompassing muscles, nerves, and blood vessels. Although locally aggressive, meaning they can grow and invade nearby structures, desmoid tumors differ from traditional cancers as they do not metastasize to distant parts of the body.
The primary treatments for desmoid tumors encompass surgical intervention, radiation therapy, anti-inflammatory medications, hormone therapy, chemotherapy, novel molecular-targeted therapy, and other therapeutic approaches. Surgery involves the removal or repair of tissues or organs within the body. The diagnosis of desmoid tumors employs various methods such as biopsy, electron microscopic examination, immunohistochemical analysis, and others. Medical professionals in hospitals, clinics, specialty centers, and similar healthcare facilities typically undertake these diagnostic and treatment procedures.
The desmoid tumors market research report is one of a series of new reports that provides desmoid tumors market statistics, including desmoid tumors industry global market size, regional shares, competitors with a desmoid tumors market share, detailed desmoid tumors market segments, market trends and opportunities, and any further data you may need to thrive in the desmoid tumors industry. This desmoid tumors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The desmoid tumors market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.18 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to advancements in medical imaging, genetic research and understanding, surgical innovations, awareness and education, patient advocacy.
The desmoid tumors market size is expected to see strong growth in the next few years. It will grow to $4.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to targeted therapies, personalized medicine, expanded international collaborations, regulatory approvals for novel therapies, patient-centric approaches. Major trends in the forecast period include advancements in treatment approaches, precision medicine and biomarker discovery, clinical trials and research initiatives, multidisciplinary treatment teams, patient advocacy and support.
The increasing incidence of cancer is anticipated to drive the growth of the desmoid tumor market in the future. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade nearby tissues and organs, causing significant harm. The global rise in cancer cases has spurred demand for advanced and effective chemotherapeutic agents, positively impacting the desmoid tumor market. For example, in May 2024, according to the National Cancer Institute, a U.S.-based federal government agency, an estimated 2,001,140 new cases of cancer are expected to be diagnosed in the U.S. in 2024, with 611,720 projected deaths from the disease. In 2022, nearly 20 million new cases and 9.7 million cancer-related deaths were reported worldwide. By 2040, the annual number of new cancer cases is expected to increase to 29.9 million, with cancer-related deaths projected to reach 15.3 million. Consequently, the rising cancer cases are driving the growth of the desmoid tumor market.
The increasing allocation of government funding for research and development is expected to boost the desmoid tumor market. Government funding plays a pivotal role in advancing tumor research and treatment by providing financial support for scientific studies, medical infrastructure, and improved access to care. This ultimately enhances cancer prevention, diagnosis, and patient outcomes. An example is the budget of $7.3 billion allocated to the National Cancer Institute by the United States Congress in fiscal year 2023 for the Cancer Moonshot, marking a $408 million increase from 2022. Consequently, the escalating government funding for research and development is fostering the growth of the desmoid tumor market.
Key companies in the desmoid tumors market are focusing on developing innovative drugs, such as nirogacestat, to address the needs of their existing consumers more effectively. Nirogacestat, an oral, small-molecule gamma-secretase inhibitor, has shown promise for treating desmoid tumors by blocking the production of notch proteins, contributing to tumor cell death. In February 2023, SpringWorks Therapeutics Inc. announced the acceptance and priority review of their new drug application (NDA) for nirogacestat by the U.S. Food and Drug Administration (FDA). This development provides patients with a new treatment option that holds the potential to improve outcomes.
In January 2023, the merger of Advaxis Inc. with Ayala Pharmaceuticals Inc., a US-based biotechnology company, aims to create a unified entity focused on developing and commercializing Ayala's lead program, AL102, for desmoid tumor treatment. The merger intends to expedite the development and commercialization of AL102, fostering a more diversified and robust cancer portfolio. Ayala Pharmaceuticals Inc. is actively developing AL102, a vaccine candidate designed to address the treatment of desmoid tumors.
Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company, Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG.
North America was the largest region in the desmoid tumors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the desmoid tumors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The desmoid tumors market consists of revenues earned by entities by providing services such as gleevec-based therapy, sorafenib-based therapy, long-term monitoring, resonance imaging (MRI), computed tomography (CT) scans, ultrasound, and fine needle aspiration techniques (FNA) that aid in the diagnosis of desmoid tumors. The market value includes the value of related goods sold by the service provider or included within the service offering. The desmoid tumors market also includes sales of surgical tools, linear accelerators, immunotherapy drugs, and anti-fibrotic agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Desmoid tumors are rare non-cancerous (benign) growths originating from connective tissue cells, typically within the fascia - the tissue encompassing muscles, nerves, and blood vessels. Although locally aggressive, meaning they can grow and invade nearby structures, desmoid tumors differ from traditional cancers as they do not metastasize to distant parts of the body.
The primary treatments for desmoid tumors encompass surgical intervention, radiation therapy, anti-inflammatory medications, hormone therapy, chemotherapy, novel molecular-targeted therapy, and other therapeutic approaches. Surgery involves the removal or repair of tissues or organs within the body. The diagnosis of desmoid tumors employs various methods such as biopsy, electron microscopic examination, immunohistochemical analysis, and others. Medical professionals in hospitals, clinics, specialty centers, and similar healthcare facilities typically undertake these diagnostic and treatment procedures.
The desmoid tumors market research report is one of a series of new reports that provides desmoid tumors market statistics, including desmoid tumors industry global market size, regional shares, competitors with a desmoid tumors market share, detailed desmoid tumors market segments, market trends and opportunities, and any further data you may need to thrive in the desmoid tumors industry. This desmoid tumors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Desmoid Tumors Market Characteristics3. Desmoid Tumors Market Trends and Strategies4. Desmoid Tumors Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Covid and Recovery on the Market32. Global Desmoid Tumors Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Desmoid Tumors Market34. Recent Developments in the Desmoid Tumors Market
5. Global Desmoid Tumors Growth Analysis and Strategic Analysis Framework
6. Desmoid Tumors Market Segmentation
7. Desmoid Tumors Market Regional and Country Analysis
8. Asia-Pacific Desmoid Tumors Market
9. China Desmoid Tumors Market
10. India Desmoid Tumors Market
11. Japan Desmoid Tumors Market
12. Australia Desmoid Tumors Market
13. Indonesia Desmoid Tumors Market
14. South Korea Desmoid Tumors Market
15. Western Europe Desmoid Tumors Market
16. UK Desmoid Tumors Market
17. Germany Desmoid Tumors Market
18. France Desmoid Tumors Market
19. Italy Desmoid Tumors Market
20. Spain Desmoid Tumors Market
21. Eastern Europe Desmoid Tumors Market
22. Russia Desmoid Tumors Market
23. North America Desmoid Tumors Market
24. USA Desmoid Tumors Market
25. Canada Desmoid Tumors Market
26. South America Desmoid Tumors Market
27. Brazil Desmoid Tumors Market
28. Middle East Desmoid Tumors Market
29. Africa Desmoid Tumors Market
30. Desmoid Tumors Market Competitive Landscape and Company Profiles
31. Desmoid Tumors Market Other Major and Innovative Companies
35. Desmoid Tumors Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Desmoid Tumors Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on desmoid tumors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for desmoid tumors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The desmoid tumors market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment: Surgery; Radiation Therapy; Anti-Inflammatory Medication; Hormone Therapy; Chemotherapy; Novel Molecular-Targeted Therapy; Other Treatments2) By Diagnosis: Biopsy; Electron Microscopic Examination; Immunohistochemical Analysis; Other Diagnosis
3) By End-User: Hospitals And Clinics; Specialty Centers; Other End-Users
Subsegments:
1) By Surgery: Wide Excision; Minimally Invasive Surgery2) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy
3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroids
4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors
5) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy
6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors; Other Targeted Therapies
7) By Other Treatments: Watchful Waiting; Physical Therapy; Pain Management Strategies
Key Companies Mentioned: Pfizer Inc.; F.Hoffmann-La Roche Ltd.; Abbvie Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Desmoid Tumors market report include:- Pfizer Inc.
- F.Hoffmann-La Roche Ltd.
- Abbvie Inc.
- Bayer AG
- Novartis AG
- Abbott Laboratories
- Amgen Inc.
- Stryker Corporation
- Genome And Company
- Vertex Pharmaceuticals Incorporated
- Eisai Limited
- Beckman Coulter Inc.
- Incyte Corporation
- Ipsen Biopharmaceuticals Inc.
- BeiGene Ltd.
- Janssen Biotech Inc.
- Ionis Pharmaceuticals Inc.
- Ayala Pharmaceuticals Inc.
- Blueprint Medicines Corporation
- Xencor Inc.
- MacroGenics Inc.
- Debiopharm Group
- Clovis Oncology Inc.
- Juno Therapeutics Inc.
- SpringWorks Therapeutics Inc.
- Loxo Oncology Inc.
- Mirati Therapeutics Inc.
- Iterion Therapeutics Inc.
- Recepta Pharmaceuticals Inc.
- Cellestia Biotech AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 3.18 Billion |
| Forecasted Market Value ( USD | $ 4.13 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
